AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
Last trade$7.55
Day change-$0.185 (-2.39%)
Day range$7.54 – $7.72
Volume809,122
Market cap$1.06B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.06B
Price / earnings
—
Price / book
0.86×
Price / sales
0.33×
EV / sales
0.91×
EV / EBITDA
5.55×
Profitability
Earnings per share
-$2.98
Return on assets
-9.68%
Return on equity
-33.18%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.55×
Current ratio
1.13×
Quick ratio
0.98×
Cash ratio
0.11×
Cash flow
Price / cash flow
1.82×
Price / free cash flow
12.88×
Free cash flow
$81.92M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AHCO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$745.65M
$740.31M
$819.8M
$846.29M
$672.37M
$657.1M
$777.88M
$856.65M
Cost of revenue
$630.84M
$636.1M
$708.3M
$674.13M
$533.85M
$521.31M
$657.44M
$664.44M
Gross profit
$114.81M
$104.21M
$111.5M
$172.16M
$138.52M
$135.79M
$120.44M
$192.21M
Selling, general and administrative
$88.66M
$96.09M
$95.91M
$107.89M
$88.14M
$95.26M
$86.85M
$83.52M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$282.73M
$248.28M
$106.01M
$245.82M
$95.15M
$102.32M
$97.27M
$94.54M
Operating income
-$167.92M
-$144.07M
$5.49M
-$73.66M
$43.37M
$33.47M
$23.17M
$97.67M
Interest expense
-$28.6M
-$26.21M
-$25.59M
$0
-$25.38M
-$27.53M
-$28.4M
$0
Income before taxes
-$184.52M
-$165.33M
-$20.11M
-$97.99M
$17.99M
$38.16M
-$5.23M
$70.71M
Income taxes
-$17.49M
-$21.23M
-$5.23M
$3.54M
$6.52M
$32.78M
$850K
$19.31M
Net income
-$152.77M
-$132.72M
-$14.87M
-$101.54M
$25.75M
$15.83M
-$6.08M
$51.4M
Net income attributable to common shareholders
-$153.99M
-$133.93M
-$16.04M
-$102.77M
$24.51M
$14.67M
-$7.21M
$42.59M
EBITDA
$133.73M
$120.46M
$111.96M
$151.85M
$141.09M
$125.83M
$117.52M
$188.2M
Basic earnings per share
-$1.13
-$0.99
-$0.12
-$0.76
$0.17
$0.10
-$0.05
$0.32
Diluted earnings per share
-$1.13
-$0.99
-$0.12
-$0.78
$0.17
$0.10
-$0.05
$0.31
Recent news
Company coverage with links to the original publishers.
Shareholder class action lawsuits have been filed against Blaize Holdings, Inc. for allegedly making false statements about business transactions and improperly recognizing revenue. The lawsuit covers investors who purchased shares between July 18, 2025 and April 28, 2026. Additionally, Holzer & Holzer, LLC announced an investigation into AdaptHealth Corp. regarding potential federal securities law violations.
AdaptHealth reported lower Q2 2025 revenue and profits, with challenges in Diabetes and Sleep Health segments. The company divested certain assets, reduced debt, and maintained cautious guidance for fiscal 2025.
The article highlights four undervalued stocks under $10 with significant growth potential across digital advertising, home healthcare, energy infrastructure, and social media sectors, each offering potential upside between 43-55%.
AdaptHealth, a home healthcare services company, reported weaker-than-expected Q3 results, missing analyst estimates for revenue and earnings. The company also reduced its full-year guidance for revenue and adjusted EBITDA, citing growth opportunities and investments. However, it lifted its 2024 free cash flow guidance.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.